NASDAQ · CCCC
C4 Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for CCCC: Nov 5, 2026
C4 Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.2. The reported EPS for the same quarter last year was $-0.44.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.20 | $-0.17 | $-0.22 | 3 |
| Dec 2026 | $-0.24 | $-0.19 | $-0.30 | 3 |
| Mar 2027 | $-0.20 | $-0.20 | $-0.20 | 1 |
| Jun 2027 | $-0.21 | $-0.21 | $-0.21 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · Zacks · RTTNews- Fintel · Oct 29, 10:31 PM EDTLake Street Initiates Coverage of C4 Therapeutics with BuyFintel reports that on October 28, 2026, Lake Street initiated coverage of C4 Therapeutics (NASDAQGS:CCCC) with a Buy recommendation.Prior to this rating action, the stock closed at $3.22 on October 27, 2026, and subsequently closed at $3.39 on October 28, 2026. C4 Therapeutics h
- Zacks · Oct 29, 9:00 AM EDTC4 Therapeutics, Inc. (CCCC) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 ReleaseC4 Therapeutics (CCCC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 9, 8:40 AM EDTIs MacroGenics (MGNX) Stock Outpacing Its Medical Peers This Year?Here is how MacroGenics (MGNX) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
- RTTNews · Sep 25, 11:07 AM EDTCemsidomide Shows Immune Activation In C4 Therapeutics' Myeloma Study(RTTNews) – C4 Therapeutics Inc. (CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation, presented new biomarker data from its Phase 1 trial of cemsidomide with dexamethasone and its Phase 1b trial of cemsidomide with elranatamab (ELREXFIO) in
- Zacks · Sep 23, 9:40 AM EDTAre Medical Stocks Lagging C4 Therapeutics (CCCC) This Year?Here is how C4 Therapeutics, Inc. (CCCC) and MacroGenics (MGNX) have performed compared to their sector so far this year.
- Zacks · Aug 21, 12:00 PM EDTAre You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great ChoiceDoes C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
- RTTNews · Aug 13, 11:13 AM EDTC4 Therapeutics Narrows Loss In Q2; Phase 2 Trial's ORR Data Due In H2 FY27(RTTNews) – C4 Therapeutics, Inc. (CCCC), a clinical-stage biotech company, released second-quarter results, with its net loss narrowing due to revenue from a collaboration agreement.
- Zacks · Aug 11, 8:15 AM EDTC4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Tops Revenue EstimatesC4 Therapeutics (CCCC) delivered earnings and revenue surprises of +21.74% and +10.68%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Jul 7, 9:40 AM EDTIs C4 Therapeutics (CCCC) Stock Outpacing Its Medical Peers This Year?Here is how C4 Therapeutics, Inc. (CCCC) and Illumina (ILMN) have performed compared to their sector so far this year.
- Zacks · Jul 3, 12:00 PM EDTC4 Therapeutics, Inc. (CCCC) Is Up 2.65% in One Week: What You Should KnowDoes C4 Therapeutics, Inc. (CCCC) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Zacks · Jun 1, 12:00 PM EDTC4 Therapeutics (CCCC) Upgraded to Buy: What Does It Mean for the Stock?C4 Therapeutics (CCCC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks · Jun 1, 9:40 AM EDTHas ABCELLERA BIOLG (ABCL) Outpaced Other Medical Stocks This Year?Here is how AbCellera Biologics Inc. (ABCL) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for C4 Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.